LISIKRIS

This brand name is authorized in Nigeria.

Active ingredients

The drug LISIKRIS contains one active pharmaceutical ingredient (API):

1	Lisinopril UNII E7199S1YWR - LISINOPRIL
	Lisinopril is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin-converting enzyme (ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased concentrations of angiotensin II which results in decreased vasopressor activity and reduced aldosterone secretion.
	Read more about Lisinopril

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-6326	Tablet	Lisikris+++ TAB 10 mg 2 x 14's (in PVC-AIu blisters)	Oral tablets A white colored, caplet shape, uncoated embossed with break-line on one side and plain on other side 6/20/2024 12:27:12 LISIKRIS Lisinopril 10mg Tablets B4-6326 Tablet Oral Lisinopril Dihydrate equivalent to Lisinopril Anhydrous 10mg 2x14 Tablets POM Krishat Pharma Industries Limited KM 15, Lagos Ibadan Expressway, Ibadan, Oyo state, Nigeria Krishat Pharma Industries Limited KM 15, Lagos Ibadan Expressway, Opp. Oriental Foods, Ibadan, Oyo state, Nigeria Nigeria 10/11/2020 09/11/2025 Yes C09AA03	10/11/2020

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C09AA03	Lisinopril	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain
Discover more medicines within C09AA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-6326